Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Tercica Stories

2013-02-13 08:27:13

NES-ZIONA, Israel, Feb. 13, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the European Commission and the European Medicines Agency (EMA) have granted orphan drug designation to hGH-CTP, PROLOR's longer-acting version of human growth hormone in development for the treatment of growth hormone deficiency. PROLOR will receive 10 years of marketing exclusivity in Europe for hGH-CTP, beginning at product launch. This is the first time a growth hormone product...

2012-09-21 02:23:24

LEIPZIG, Germany and NES-ZIONA, Israel, Sept. 21, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that data from the company's Phase II trial of hGH-CTP, its long acting human growth hormone, in growth hormone deficient adults will be presented at ESPE 2012, the 51st Annual Meeting of the European Society for Paediatric Endocrinology. The previously reported data confirmed that a single weekly injection of hGH-CTP has the potential to reduce the required dosing...

2012-05-14 10:25:02

SAN DIEGO, May 14, 2012 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that it will be added to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective Monday, May 21, 2012. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB)...

2009-02-25 05:00:00

SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the appointment of John A. Scarlett, M.D., to the position of President and Chief Executive Officer. Dr. Scarlett brings nearly 30 years of experience in drug development and commercialization to his new role. Susan Molineaux, Ph.D., who founded Proteolix in 2003, will...

2008-11-14 09:00:34

Ambrx, a clinical stage biopharmaceutical company, has announced positive Phase I/II clinical trial data demonstrating that ARX201, the company's long-acting human growth hormone analogue developed in collaboration with Merck Serono, normalized insulin-like growth factor I levels while delivering an acceptable safety and tolerability profile in adults with growth hormone deficiency. The Phase I/II study of ARX201, analyzed 22 adult growth hormone deficiency (AGHD) patients who had not...

2008-10-17 03:00:16

Regulatory News: Ipsen (Paris:IPN) announced today that stockholders of Tercica, Inc. (Nasdaq:TRCA) voted to approve its previously announced acquisition of Tercica at a special meeting of shareholders held on 16 October 2008 in Brisbane, California. Over 90% of the approximately 68.5 million total votable shares were cast in favour of the transaction. Following the meeting, the closing was completed, the merger certificate was filed and the merger became effective as of 16 October 2008....

2008-06-16 15:00:49

Tercica, Inc. (NASDAQ: TRCA) today announced the first results from the Increlex(R) Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco. Increlex(R) (mecasermin (rDNA origin) injection) is currently approved in the United States for the treatment of severe Primary IGF-1 Deficiency. "Data from the IGFD Registry showed that children treated with Increlex(R) at the higher end of the recommended-dose range (greater...